We next examined PD-L1 and PD-L2 gene expression by qRT-PCR in a panel of low passage (≤5 passages from initial culture) patient-derived brain tumor initiating cell (BTIC) lines established from patients with newly diagnosed GBM18. This evidence concerns the gene PDCD1LG2 and brain neoplasm.